Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.
Not Applicable
- Conditions
- Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis
- Registration Number
- JPRN-UMIN000024312
- Lead Sponsor
- Tsukuba International Clinical Pharmacology Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1.Subjects taking azathioprine or mercaptopurine 2.Subject who has or had renal function disorder. 3.Subject with a history of gout, hyperuricemia or urolithiasis. 4.Subject who has a history of renal disorder. 5.Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 6.Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of HDS-R (Alzheimer's disease), Yahr's classification (Parkinson's disease), EDSS (multiple sclerosis) and ALSFRS-R (amyotrophic lateral sclerosis) by 2-week treatment with febuxostat and inosine
- Secondary Outcome Measures
Name Time Method